China Medical System Holdings Limited (the 'Group” or 'CMS”) is pleased to announce that on 11 December 2025, the New Drug ...

Povorcitinib is a selective oral small-molecule JAK1 inhibitor, with compound and use patents in certain countries/regions in the Territory. Currently, povorcitinib is in Phase 3 clinical trials for ...

Pune's strong foundation in automotive, defense, and manufacturing has cultivated a unique \"product-thinking\" culture, ...

Europe's biggest aerospace company Airbus reportedly wants to move away from two of the biggest American technology companies ...

If there's one simple, inexpensive and charming item that can transform any Christmas decoration, it's dried oranges. As well ...

As AI moves to operational reality, PLM companies are prioritizing faster decisions and agentic intelligence integration over ...

The Trump administration has unveiled yet another new payment model, this one focused on the cost of GLP-1 therapies. | The Trump administration has unveiled yet another new payment model, this one ...

The Centers for Medicare & Medicaid Services (CMS) recently proposed the Guarding US Medicare Against Rising Drug Costs (GUARD) Model, a drug payment model that aims to distribute rebates for certain ...

CMS’ upcoming ACCESS payment model is being billed as a turning point in how chronic care is reimbursed and managed — aiming to tie payments to patient outcomes and expand the use of digital tools.

CMS published plans Dec. 23 for its voluntary “Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth” — or BALANCE — model. The announcement comes weeks following the White House’s ...

For companies in the biotech space, it’s never been easy to navigate the legal and business risks inherent in a highly regulated, dynamic industry – and it’s only becoming more complicated in light of ...